Beam Therapeutics (MEX:BEAM) Dividends per Share: MXN0.00 (TTM As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
67 GF Score
Price MXN628.46
GF Value MXN507.79
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Dividends per Share?

Beam Therapeutics MEX:BEAM 67 Dividends per Share is MXN0.00 as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 67/100 and a GF Value™ of MXN507.79 (Fairly Valued). The stock has 6 warning signs investors should review.

Beam Therapeutics's dividends per share for the three months ended in Mar. 2026 was MXN0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, Beam Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Beam Therapeutics  (MEX:BEAM) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Beam Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -16.939
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Dividends per Share Related Terms

Beam Therapeutics Dividends per Share Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Dividends per Share Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:BEAM vs ELVN, IDYA, PBLS: Dividends per Share Comparison

For the Biotechnology subindustry, Beam Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Dividend Yield % falls into.


MEX:BEAM
67GF Score
Beam Therapeutics Inc MEX:BEAM
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of MXN0.00 mean?
Beam Therapeutics (MEX:BEAM) has a Dividends per Share of MXN0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Dividends per Share too high?
Beam Therapeutics' current Dividends per Share is MXN0.00. Overall, Beam Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Dividends per Share compare to ELVN and IDYA?
Beam Therapeutics' Dividends per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Dividends per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN507.79, compared to a current price of MXN628.46 — trading 23.8% above its estimated fair value. The current Dividends per Share is MXN0.00. Beam Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Dividends per Share is MXN0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 23.8% above its estimated GF Value™ of MXN507.79. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Dividends per Share: MXN0.00
  • GF Value™: MXN507.79 vs. price of MXN628.46 (23.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
67GF Score

Get the complete analysis for MEX:BEAM

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN507.79
GF Value